Recombinant DENV-3 Envelope protein E, N-His

Description of Recombinant DENV-3 Envelope protein E, N-His

Introduction

Recombinant DENV-3 Envelope protein E is a synthetic protein that is derived from the envelope protein of Dengue virus serotype 3 (DENV-3). This protein has been genetically engineered in the laboratory to mimic the natural structure and function of the envelope protein found on the surface of the virus. Recombinant protein technology has allowed for the production of large quantities of this protein, which has been extensively studied for its potential use as an antigen in diagnostics and vaccine development.

Structure of Recombinant DENV-3 Envelope protein E

The structure of Recombinant DENV-3 Envelope protein E closely resembles that of the natural envelope protein found on the surface of DENV-3. It is composed of 495 amino acids and has a molecular weight of approximately 55 kDa. The protein has three distinct domains – domain I, II, and III – that are responsible for different functions. Domain I is involved in receptor binding, domain II is involved in fusion of the virus with host cells, and domain III is involved in virus assembly and maturation.

Activity of Recombinant DENV-3 Envelope protein E

Recombinant DENV-3 Envelope protein E is a highly active protein that plays a crucial role in the pathogenesis of DENV-3. It is responsible for the attachment and entry of the virus into host cells, as well as for the production of neutralizing antibodies in the host. The protein is also involved in the formation of viral particles and their release from infected cells. In addition, Recombinant DENV-3 Envelope protein E has been shown to induce a strong immune response in the host, making it a potential target for vaccine development.

Application of Recombinant DENV-3 Envelope protein E

Recombinant DENV-3 Envelope protein E has several potential applications in the field of dengue research and diagnostics. One of its main applications is as an antigen in diagnostic tests for the detection of DENV-3 infection. The protein can be used in serological assays, such as ELISA and Western blot, for the detection of antibodies against DENV-3 in patient serum. It can also be used in rapid diagnostic tests, such as lateral flow assays, for quick and accurate detection of DENV-3 infection.

Another important application of Recombinant DENV-3 Envelope protein E is in the development of dengue vaccines. The protein has been extensively studied as a potential vaccine candidate, and several studies have shown promising results. Recombinant DENV-3 Envelope protein E can be used as a subunit vaccine, where it is combined with other viral proteins to induce a strong immune response against DENV-3. It can also be used as a live attenuated vaccine, where the protein is incorporated into a weakened form of the virus that can stimulate the immune system without causing disease.

In addition to its diagnostic and vaccine applications, Recombinant DENV-3 Envelope protein E has also been studied for its potential use in therapeutic interventions. The protein has been shown to have antiviral properties, and it may be used in the development of antiviral drugs to treat dengue infections. Furthermore, Recombinant DENV-3 Envelope protein E can also be used in research studies to better understand the structure and function of the protein and its role in dengue virus infection.

Conclusion

In summary, Recombinant DENV-3 Envelope protein E is a synthetic protein that closely resembles the natural envelope protein found on the surface of DENV-3. It plays a crucial role in the pathogenesis of dengue and has several potential applications in diagnostics, vaccine development, and therapeutic interventions. Further research and development of this protein may lead to improved methods for the diagnosis, prevention, and treatment of dengue virus infection.